SCHEMBL4934407

SCHEMBL4934407

COc1cccc(C(=O)Cn2nc(Nc3cccc(Cl)c3)c3cc(OC)ccc32)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.49
AURKB Q96GD4 1/20 0.49
FADS1 O60427 2/20 0.48
CDYL2 Q8N8U2 4/20 0.46
CDYL Q9Y232 4/20 0.46
CDY1; CDY1B Q9Y6F8 4/20 0.46
CBX7 O95931 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
GFER P55789 1/20 0.45
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
RXFP1 Q9HBX9 2/20 0.43
POLB P06746 1/20 0.43
MGLL Q99685 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4741979 0.94 FADS1 (0.48) AURKAAURKBFADS1SMN1; SMN2MEN1
SCHEMBL4740979 0.87 FADS1 (0.50) FADS1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL4740978 0.87 FADS1 (0.49) FADS1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL4937692 0.86 FADS1 (0.46) FADS1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL4741010 0.86 FADS1 (0.48) FADS1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL4740936 0.83 FADS1 (0.49) FADS1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL4741728 0.82 FADS1 (0.55) FADS1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL4785627 0.81 KDR (0.54) AURKAAURKBFADS1SMN1; SMN2MEN1
SCHEMBL4739356 0.81 FADS1 (0.51) FADS1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL4785097 0.80 FADS1 (0.53) FADS1SMN1; SMN2MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC BUCK INST RES AGING (US) 2024-07-04 US disclosed
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders LEXICON PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer LEXICON PHARMACEUTICALS, INC. 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer TNF, IL6, CXCL8 AURKA 2862/4885AURKB 2767/4885FADS1 1059/4885
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC DAGLA, DAGLB, MGLL AURKA 4214/4885AURKB 2913/4885FADS1 192/4885
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders CPT1B, CPT1A, SHBG AURKA 4786/4885AURKB 4557/4885FADS1 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.